Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Immune Pharma Tackling Orphan Disease Bullous Pemphigoid

Immune Pharmaceuticals (NASDAQ:IMNP) is developing bertilimumab, a first-in-class fully human monoclonal antibody that targets eotaxin-1, a potent chemoattractant and activator of eosinophils. Immune is currently testing bertilimumab in a Phase 2 clinical trial for ulcerative colitis (UC) with plans to start a Phase 2 trial for bullous pemphigoid (BP) shortly. We believe there is a meaningful opportunity for Immune to position bertilimumab as a first-line treatment for BP due to the fact there is no cure and current treatment options have multiple, deleterious side effects. Below we give an overview of bertilimumab, BP, and the clinical development plans for the treatment for BP.

About Bertilimumab

Immune is developing bertilimumab, a first-in-class fully human IgG4 monoclonal antibody targeted against

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details